Company / Cash & Equivalents
AVITA Medical, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$10.2M
FY2025
5-year range
$10.2M / $73.6M
FY2021-FY2025
Trend
-27.1%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $22M to $10M over the past 2 years.
Based on SEC 10-K filings.
$10M in FY2025 with a 5-year CAGR of -32.6%.
Declined from $22M to $10M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -17.4%
- 5-Year CAGR
- -32.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -32.6%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 27.1% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -2.29 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $10.2M | -27.1% |
| FY2024 | $14.1M | -36.5% |
| FY2023 | $22.1M | +21.8% |
| FY2022 | $18.2M | -75.3% |
| FY2021 | $73.6M | +0.0% |
| FY2020 | $73.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026